Search results for: Value-Based Pricing

Consumer Movement, Health, and the Pharmaceutical Industry

1 January 1983

…deny the value of extensive legal and financial interventions designed to protect those in need of care and support from the hazards of an untrammelled market. Yet at the same…

Future for Pharmaceuticals: the Potential; the Pattern and the Problems

1 June 1983

…for example, electronics, nuclear energy, and those based on the latest biotechnologies. Amongst these latter, pharmaceuticals represent an outstanding and exceptional example of British achievement. It is a modern successful…

New NHS Act for 1996?

1 October 1984

…in favour of the solutions which have been discussed in the past – a reversion to ‘private’ care, or the introduction of competing insurance-based sources of finance – have not…

Policy, Organisation and Incentives in Health Systems

…certain behaviours and outcomes. The broader socioeconomic value of health interventions to the wider economy, with a particular focus on prevention (including vaccination). Key objective for this research theme To produce…

The Trajectory of Dementia in the UK – Making a Difference

1 June 2014

…in 2020. Based on the latest official UK population projections and the most authoritative estimates of the prevalence of dementia, OHE Consulting built a model to project the number of…

Handling Uncertainty in the Results of Economic Evaluation

1 September 1995

…well as clinical data and offers the potential for uncertainty to be quantified through conventional statistical techniques [O’Brien,et al, 1994]. However, most economic evaluations are based largely on deterministic data…

Industrial Policy and the Pharmaceutical Industry

1 January 1995

…European Community, Japan and the US are by Yarrow, and Professors Neary and Scherer, respectively. In the fourth paper Hale and Towse assess how valuable the UK-based pharmaceutical industry is…

Uses of Models in Economic Evaluations of Medicines and Other Health Technologies

1 October 1996

…can provide a way of turning good efficacy and cost-efficacy studies into good cost-effectiveness analyses. Of course, concerns about potential bias in data taken from non RCT based studies (see…

Health Financing and Pharmaceutical Policy Reform in the Countries of Central and Eastern Europe

12 January 1997

…straight-forward and – in comparison to the reform of other sectors such as hospital care – relatively in-expensive technology to bring about improvements in health. This report is based on…